

**ASX Announcement**  
**10 September 2020**

## Issue of AGC shares complete

**Regeneus Ltd (ASX: RGS) (Regeneus or the Company)**, a clinical-stage regenerative medicine company, today announces it has issued a total of 22,459,393 shares to Japan-based manufacturer AGC Inc (AGC), following the previous announcement made on 20 December 2019 to mutually terminate the exclusive manufacturing and joint venture agreement.

Leo Lee, CEO and Executive Director of Regeneus noted: "We welcome AGC as a strategic investor in Regeneus and are pleased they have shown confidence in our progress and commercialisation strategy. Their support is further recognition of the commercial opportunity for Progenza for the treatment of knee osteoarthritis in Japan."

**-ENDS-**

### **About Regeneus**

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit [www.regeneus.com.au](http://www.regeneus.com.au) for more information.

### **Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Regeneus Ltd

### **Investor and Media Contact**

WE Communications  
T: 02 9237 2805  
E: [WE-AURegeneus@we-worldwide.com](mailto:WE-AURegeneus@we-worldwide.com)